

# SAFETY PROFILE OF RUPATADINE IN THE TREATMENT OF CHRONIC URTICARIA

Giménez-Arnau A<sup>1</sup>, Malbran A<sup>2</sup>, Poop G<sup>3</sup>, Benea V<sup>4</sup>, Medina I<sup>5</sup>, Garcia O<sup>6</sup>, Donado E<sup>6</sup>

<sup>1</sup>Hospital del Mar, Dermatology Department, IMAS. Barcelona, Spain.

<sup>2</sup>Unidad de Alergia, Asma o Inmunología-COM. Buenos Aires, Argentina.

<sup>3</sup>Dermatological Clinical Practica. Augsburg, Germany.

<sup>4</sup>Clinical Hospital Prof Scarlat Longhin. Bucharest, Romania.

<sup>5</sup>Centro Médico Vitae. Buenos Aires, Argentina.

<sup>6</sup>J. Uriach y Compañía, SA. Barcelona, Spain.

## BACKGROUND

Chronic urticaria is defined by spontaneous wheals long-lasting more than six weeks<sup>1</sup>. Conventionally, if any apparent etiology was considered, chronic urticaria is categorized as idiopathic. Chronic idiopathic urticaria (CIU) is a relatively common skin condition. Wheals and pruritus are the most prominent sign and symptom<sup>1</sup>. The symptoms of CIU are mainly associated with dermal mast cells degranulation and histamine release. This fact has led to use inverse agonist H<sub>1</sub> antihistamines to treat the urticarias<sup>2</sup>. Chronic urticaria bleaching requires to control of multiple involved factors and also long periods of continuous treatment. Non-sedating H<sub>1</sub> antihistamines have been recommended by the EAACI / GA<sup>2</sup>LEN / EDF guideline as first line of treatment<sup>3</sup>. One of the reasons for this kind of recommendation is the good safety profile of these drugs. **Rupatadine is a new selective long-acting histamine H<sub>1</sub> receptor inverse agonist (H<sub>1</sub> antihistamine) which is currently approved as a once daily dose of 10 mg, for the treatment of chronic idiopathic urticaria<sup>5,6</sup> and allergic rhinitis<sup>7</sup>.**

## AIM

To assess Rupatadine safety profile in moderate to severe Chronic Urticaria without an identifiable aetiology or “Chronic Idiopathic Urticaria” (CIU) treatment.

## MATERIAL AND METHODS

The pooled data from two randomised, double blind and placebo controlled, 4-week multicentre studies were used for this analysis. The first was a dose-ranging study comparing the efficacy and safety of placebo or rupatadine 5 mg, 10 mg and 20 mg once daily in 283 CIU patients<sup>4</sup>. The second study compared the efficacy of placebo or rupatadine 10 mg and 20 mg once daily in 334 CIU patients<sup>5</sup>. Efficacy and safety profile was evaluated over 6 weeks of treatment.

The incidence and type of adverse events (AEs) was assessed based on the patients’ diaries reports, routine laboratory tests results, clinical and physical examinations and ECG, before and at the end of the treatment period. (Fig. 1) Descriptive statistics was applied. Incidence of AE during the 4-weeks was calculated. The qualitative parameters were described by treatment group in terms of frequencies and percentages. The initial comparability of the treatment groups concerning to demographic and anthropometric variables was analyzed, as well as clinical characteristics at the time of inclusion by means of T test, Chi square test or Fisher test according to the type of variable.

## RESULTS

Global incidence of AEs was 28.02% with placebo-treated group (n=182), 32.86% with rupatadine 5mg-treated group (n=70), 30.11% with rupatadine 10 mg-treated group (n=186) and 35.20% with rupatadine 20 mg-treated group (n=179). The 11.54%, 14.29%, 11.83% and 20.67% of the AEs respectively were related with the treatment.

The most frequents reported related AEs were headache 2.75%, 2.86%, 2.69% and 3.91% and somnolence 3.85%, 4.29%, 3.76% and 13.41% for placebo, rupatadine 5mg, rupatadine 10 mg and rupatadine 20 mg, respectively. Any of these AEs forced to discontinue the treatment.

Just somnolence AEs was significantly higher with rupatadine 20 mg than with placebo or rupatadine 10 mg. The others AEs did not show significant differences among the treatment groups. (Fig. 2 and 3)


Comparatively, in two studies with desloratadine 5mg, headache was 15.5% (placebo 10%)<sup>8</sup> and 12.6% in the study<sup>9</sup> (placebo 16.8%). In addition, in those studies there were other AEs reported such as nausea, dry mouth, fatigue, upper respiratory tract infection and dizziness...”

No clinically relevant AEs were observed related with ECG, blood testing and vital signs studies during rupatadine clinical trials. Concerning ECG no relevant findings were reported. Any patient showed a QTc value longer than 470 msec and in any case QTc increased 60 or more msec. One asymptomatic and not clinically relevant CPK increased value was reported as SAE.

Table I. Pooled CIU Demographic data (ITT population)


		Treatment				All
		Placebo	Rupatadine 5 mg	Rupatadine 10 mg	Rupatadine 20 mg	
Gender						
Male	N	58	19	52	54	183
	%	31.87	27.14	27.96	30.17	29.66
Female	N	124	51	134	125	434
	%	68.13	72.86	72.04	69.83	70.34
Age (years)		36.31	39.1	40.1	37.8	38
All	N	182	70	186	179	617

Figure 2. Incidence of global adverse events (AE) (n<1, at least one) after 4 weeks treatment



**Somnolence:** Rupatadine 20 vs. placebo, p<0.001; Rupatadine 20mg vs. Rupatadine 10mg p<0.001  
**Headache:** No differences between treatments

Figure 3. Incidence of related adverse events (AE) (n<1, at least one) after 4-weeks treatment



**Somnolence:** Rupatadine 20 versus placebo, p<0.001; Rupatadine 20mg versus Rupatadine 10mg p<0.001  
**Headache:** No differences between treatments

## CONCLUSION

All dosages of rupatadine administered once daily during these two clinical trials showed to be safe and well tolerated. Rupatadine can be recommended as first line treatment for moderate-to-severe Chronic Urticaria without an identifiable aetiology.

## ACKNOWLEDGEMENTS

The authors would like to thank J. Uriach y Compañía S.A. (Barcelona, Spain) for its financial support to this study. This study was partially supported by the National Scientific Research Program of the Spanish Minister of Science and Technology.

## REFERENCES

- Greaves MW. Chronic Urticaria. N Engl J Med 1995; 322: 1767-1772.
- Kozel MMA, Sabroe RA. Chronic Urticaria. Etiology, management and current future treatment options. Drugs 2004; 64: 2515-36.
- Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan EH, Greaves MW, Henz BM, Kapp A, Kozel MMA, Maurer M, Merk HF, Schäfer T, Simon D, Vena GA, Wedi B. EAACI/ GA2LEN/ EDF guideline: management of urticaria. Allergy 2006; 61: 321-331
- Izquierdo I, Merlos M, García-Rafanell J. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs of today 2003; 39:451-468.
- Dubertret L, Zalupca L, Cristodoulo T, Benea V, Medina M, Fantin S, Lahfa M, Pérez P, Izquierdo I, Arnaiz E. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. 2007. In press.
- Gimenez-Arnau A, Pujol RM, Ianos S, Kaszuba A, Malbran A, Poop G, Donado E, Perez I, Izquierdo I, Arnaiz E. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicenter study. Allergy 2007; 62(5): 539-546.
- Merlos M, Giral M; Balsa D, Ferrando Q, Queralt M, Puigdemont A, García-Rafanell J and Forn J. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 1997; 280:114-121.
- Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D and the Desloratadine Urticaria Study Group. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003; 48: 535-541.
- Ring J, Hein R, Gauger A, Bronsky E, Miller B, and the Desloratadine Study Group. International Journal of Dermatology 2001; 40: 1-5.